MEC Basic – MyMedflix Member Portal

Renal Cell Carcinoma Updates

Renal Cell Carcinoma Updates

Scott Tykodi, MD

ASCO GI 2024 Updates

ASCO GI 2024 Updates

David B. Zhen, MD

Head and Neck Cancer 2024 Updates

Head and Neck Cancer 2024 Updates

Cristina P. Rodriguez, MD

HER2 Targeted Therapies: Recent Advances

HER2 Targeted Therapies: Recent Advances

Helen Chew, MD, FACP

New Biomarkers in Breast Cancer

New Biomarkers in Breast Cancer

Joanne Mortimer, MD, FACP, FASCO

Immunotherapy for Breast Cancer: When to Use and Future Directions

Immunotherapy for Breast Cancer: When to Use and Future Directions

Evanthia Torres, MD, PhD

Hormone Therapy in Breast Cancer: New Directions

Hormone Therapy in Breast Cancer: New Directions

Mili Arora, MD

Targeting the Microbiome and Optimizing Immunotherapy in Cancer

Targeting the Microbiome and Optimizing Immunotherapy in Cancer

Sumanta K. Pal, MD, FASCO

Targeting RAS-RAF-MAPK Pathway

Targeting RAS-RAF-MAPK Pathway

Jacob Thomas, MD

Hippo-Yap Pathway

Hippo-Yap Pathway

Janai Carr-Ascher, MD, PhD

Novel Targets in Hematologic Malignancies

Novel Targets in Hematologic Malignancies

Tycel Phillips, MD

Lymphoma: State of the Art

Lymphoma: State of the Art

Alexey Danilov, MD, PhD

AML and MDS: New Directions

AML and MDS: New Directions

Olatoyosi Odenike, MD

Systemic Therapy in Urothelial Carcinoma

Systemic Therapy in Urothelial Carcinoma

Sarmad Sadeghi, MD, PhD

Management of Renal Cell Carcinoma

Management of Renal Cell Carcinoma

Shuchi Gulati, MD, MS, FACP

Castration Resistant Prostate Cancer: What is the Optimal Strategy?

Castration Resistant Prostate Cancer: What is the Optimal Strategy?

Mamta Parikh, MD, MS

State of the Art: Hormone-sensitive Prostate Cancer

State of the Art: Hormone-sensitive Prostate Cancer

Abhishek Tripathi, MD

Precision Oncology and Landmark Advances in GU Malignancies

Precision Oncology and Landmark Advances in GU Malignancies

Walter M. Stadler, MD, FACP

Updates in Locally Advanced Unresectable (Stage III) NSCLC

Updates in Locally Advanced Unresectable (Stage III) NSCLC

Jorge Nieva, MD

Advances in Limited and Extensive Stage Small Cell Lung Cancer

Advances in Limited and Extensive Stage Small Cell Lung Cancer

Jyoti Malhotra, MD, MPH

Updates in NSCLC Targeted Therapy

Updates in NSCLC Targeted Therapy

Jonathan W. Riess, MD, MS

Updates in Immunotherapy for Metastatic Lung Cancer

Updates in Immunotherapy for Metastatic Lung Cancer

Erminia Massarelli, MD, PhD, MS

New Developments in Esophageal and Gastric Cancer

New Developments in Esophageal and Gastric Cancer

Sandra Algaze, MD

Recent Advances in Colorectal Cancer

Recent Advances in Colorectal Cancer

Heinz-Josef Lenz, MD, FACP

Updates in the Management of Pancreatic Cancer

Updates in the Management of Pancreatic Cancer

Vincent Chung, MD, FACP

Advances in Cellular Therapies for Cancer

Advances in Cellular Therapies for Cancer

Mohamed Abou-el-Enein, MD, PhD, MSPH

Advances in Non-PD(L)1 Immunotherapies in Solid Tumors

Advances in Non-PD(L)1 Immunotherapies in Solid Tumors

Miguel Villalona-Calero, MD

Perioperative Therapy and Predictive Biomarkers in Early Stage Non Small Cell Lung Cancer

Perioperative Therapy and Predictive Biomarkers in Early Stage Non Small Cell Lung Cancer

David Gandara, MD

Overview on How to Submit a Clinical Letter of Intent (LOI) to NCI/CTEP

Overview on How to Submit a Clinical Letter of Intent (LOI) to NCI/CTEP

S. Percy Ivy, MD

Expansion Cohorts in Early Phase Clinical Trials: Valuable or Not?

Expansion Cohorts in Early Phase Clinical Trials: Valuable or Not?

Paul Frankel, PhD